Twist Bioscience Corporation
Health
Performance
7.9
Risk
Sell
Buy
Curious about the Scores? Learn more.

Twist Bioscience Corporation stock rating and score history

All changes in ratings, performance and outlook tracked over time.

22.07.2026
Off life support. Still risky, but slightly less scary.
27.05.2026
Picking up speed. Momentum turning positive.
22.05.2026
Barely upright. Still chaotic, but slowly finding some balance.
01.01.2026
Danger zone. Balance sheet’s flashing red across the board.
TWST
Twist Bioscience Corporation
95.86
+9.62%
7.9
Sell
Buy
Twist Bioscience Corporation

Twist Bioscience Corporation stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Twist Bioscience Corporation do? Business model and key facts

Get the full picture of Twist Bioscience Corporation: what it builds, where it operates, and how it makes money.

Twist Bioscience Corporation Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 979

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

shop
Company facts
Emily Marine Leproust
CEO
979
Employees worldwide
shop
Performance
175.7%
Last 12 months
-22.08%
Last 5 years
shop
Growth
$376.57M
Revenue year
$-77,670,000
Net income
shop
Valuation
$5.84B
Market Cap
-21.65
Price/Earnings Ratio

Stocks related to Twist Bioscience Corporation

Selected based on industry alignment and relative market positioning.

QGEN
Qiagen N.V.
40.53
+0.12%
5.2
Sell
Buy
Qiagen N.V.
CRL
Charles River Laboratories International, Inc.
219.40
-0.14%
5.6
Sell
Buy
Charles River Laboratories International, Inc.
RVTY
Revvity, Inc.
110.52
+3.83%
4.3
Sell
Buy
Revvity, Inc.
SHC
Sotera Health Company
17.40
-0.11%
5.1
Sell
Buy
Sotera Health Company
RDNT
RadNet, Inc.
61.87
+1.96%
7.0
Sell
Buy
RadNet, Inc.

Events and news impacting Twist Bioscience Corporation stock

Earnings, coporate decisions and industry developments that can affect the share price.

Twist Bioscience Corporation fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.